tetano
Editor, Senior Moderator
Cardiol Discov
. 2021 Dec 3;1(1):37-43.
doi: 10.1097/CD9.0000000000000014. eCollection 2021 Mar.
Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
Hesong Zeng[SUP] 1 [/SUP], Xingwei He[SUP] 1 [/SUP], Wanjun Liu[SUP] 1 [/SUP], Jing Kan[SUP] 2 [/SUP], Liqun He[SUP] 3 [/SUP], Jinhe Zhao[SUP] 4 [/SUP], Cynthia Chen[SUP] 5 [/SUP], Junjie Zhang[SUP] 2 [/SUP], Shaoliang Chen[SUP] 1 2 6 [/SUP]
Affiliations
Abstract
Objective: Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).
Methods: This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.
Results: Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598-4.659).
Conclusions: Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.
Keywords: Abidol; Coronavirus induced disease; In-hospital death; Inflammation.
. 2021 Dec 3;1(1):37-43.
doi: 10.1097/CD9.0000000000000014. eCollection 2021 Mar.
Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
Hesong Zeng[SUP] 1 [/SUP], Xingwei He[SUP] 1 [/SUP], Wanjun Liu[SUP] 1 [/SUP], Jing Kan[SUP] 2 [/SUP], Liqun He[SUP] 3 [/SUP], Jinhe Zhao[SUP] 4 [/SUP], Cynthia Chen[SUP] 5 [/SUP], Junjie Zhang[SUP] 2 [/SUP], Shaoliang Chen[SUP] 1 2 6 [/SUP]
Affiliations
- PMID: 34977907
- PMCID: PMC8710295
- DOI: 10.1097/CD9.0000000000000014
Abstract
Objective: Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).
Methods: This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.
Results: Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598-4.659).
Conclusions: Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.
Keywords: Abidol; Coronavirus induced disease; In-hospital death; Inflammation.